4D Molecular Therapeutics (FDMT) Enterprise Value: 2019-2025
Historic Enterprise Value for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $100.8 million.
- 4D Molecular Therapeutics' Enterprise Value rose 68.25% to $100.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$938.8 million, marking a year-over-year increase of 27.58%. This contributed to the annual value of -$167.4 million for FY2024, which is 128.96% down from last year.
- Per 4D Molecular Therapeutics' latest filing, its Enterprise Value stood at $100.8 million for Q3 2025, which was up 183.04% from -$121.4 million recorded in Q2 2025.
- 4D Molecular Therapeutics' 5-year Enterprise Value high stood at $1.1 billion for Q1 2024, and its period low was -$171.9 million during Q1 2025.
- Moreover, its 3-year median value for Enterprise Value was $215.7 million (2023), whereas its average is $250.8 million.
- In the last 5 years, 4D Molecular Therapeutics' Enterprise Value spiked by 1,959.05% in 2023 and then tumbled by 128.96% in 2024.
- 4D Molecular Therapeutics' Enterprise Value (Quarterly) stood at $457.3 million in 2021, then grew by 10.61% to $505.9 million in 2022, then climbed by 14.25% to $578.0 million in 2023, then slumped by 128.96% to -$167.4 million in 2024, then soared by 68.25% to $100.8 million in 2025.
- Its Enterprise Value was $100.8 million in Q3 2025, compared to -$121.4 million in Q2 2025 and -$171.9 million in Q1 2025.